Close

Endo Int'l (ENDP) Announces Statistically Significant Data from Xiaflex Phase 2 in Dupuytren's Disease Nodules

Go back to Endo Int'l (ENDP) Announces Statistically Significant Data from Xiaflex Phase 2 in Dupuytren's Disease Nodules

Northland Capital Markets Upgrades Endo International plc (ENDP) to Outperform

September 29, 2016 9:02 AM EDT

Northland Capital Markets upgraded Endo International plc (NASDAQ: ENDP) from Market Perform to Outperform with a price target of $27.00.

For an analyst ratings summary and ratings history on Endo International plc click... More

Mizuho Securities Reiterates Outperform Following Endo Int'l (ENDP) Sell-Side Meeting

September 29, 2016 7:10 AM EDT

Mizuho Securities reiterated an Outperform rating and $29.00 price target on Endo International plc (NASDAQ: ENDP) following a sell-side meeting with management. The company's CEO, Paul Campanelli indicated that there should be a business update in February following its Board meeting.

Analyst Irina Koffler commented, "Mgmt hosted a sell-side meeting at its Par facility which included a plant tour. Our takeaways from the visit are as follow: (1) Mgmt is still... More